In silico identification of novel EGFR inhibitors with antiproliferative activity against cancer cells
- 18 January 2006
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 16 (7), 1969-1974
- https://doi.org/10.1016/j.bmcl.2005.12.067
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Structural Bioinformatics-Based Design of Selective, Irreversible Kinase InhibitorsScience, 2005
- The ErbB Receptors and their Ligands in Cancer: An OverviewCurrent Drug Targets, 2005
- A small molecule–kinase interaction map for clinical kinase inhibitorsNature Biotechnology, 2005
- High-throughput X-ray crystallography for drug discoveryCurrent Opinion in Pharmacology, 2004
- Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2003
- Issues and progress with protein kinase inhibitors for cancer treatmentNature Reviews Drug Discovery, 2003
- Smart drugs: Tyrosine kinase inhibitors in cancer therapyCancer Cell, 2002
- Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growthAnnals of Oncology, 2002
- Tyrosine kinase inhibitors: Rationale, mechanisms of action, and implications for drug resistanceSeminars in Oncology, 2001
- Untangling the ErbB signalling networkNature Reviews Molecular Cell Biology, 2001